Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B

by Zacks Equity Research

Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.

Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails

by Zacks Equity Research

Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK

by Kinjel Shah

Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.

BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag

by Zacks Equity Research

FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.

Roche (RHHBY) Withdraws Bladder Cancer Indication for Tecentriq

by Zacks Equity Research

Roche (RHHBY) voluntarily withdraws the bladder cancer indication of Tecentriq in the United States.

Pfizer's (PFE) Lorbrena Gets FDA Nod for First-Line Lung Cancer

by Zacks Equity Research

Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets approval in the United States.

Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold

by Zacks Equity Research

Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.

Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall

by Zacks Equity Research

Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

Epizyme's (EPZM) Q4 Loss Wider than Expected, Sales Beat

by Zacks Equity Research

Epizyme (EPZM) incurs a wider-than-expected loss but beats sales estimates in the fourth quarter of 2020.

Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls

by Zacks Equity Research

Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.

Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Seagen (SGEN) Gets European Commission Nod for Breast Cancer Drug

by Zacks Equity Research

The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.

ImmunoGen (IMGN) Q4 Earnings & Sales Top, Pipeline on Track

by Zacks Equity Research

ImmunoGen (IMGN) reports encouraging fourth-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.

Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.

TEVA Stock Declines Despite Q4 Earnings and Sales Beat

by Zacks Equity Research

TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19

by Zacks Equity Research

Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

New Strong Sell Stocks for February 5th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates

by Zacks Equity Research

Biogen's (BIIB) earnings lag estimates in the fourth quarter of 2020, while revenues surpass the same. Tecfidera generics continues to hurt sales. The company provides revenues guidance for 2021.

AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright

by Zacks Equity Research

AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Amgen (AMGN) Q4 Earnings & Sales Top, 2021 Outlook Dull

by Zacks Equity Research

Amgen (AMGN) beats Q4 estimates for both earnings and sales. Shares decline in after-hours trading.

Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?

by Zacks Equity Research

AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

by Zacks Equity Research

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.